CancerWorld shared a post on LinkedIn:
“A potential turning point in pancreatic cancer?
‘It’s the first time that a targeted therapy has shown such promise in metastatic pancreatic cancer.’
In CancerWorld, Mariam Khachatryan interviews Dr. Shiraj Sen on the emerging data behind daraxonrasib, a RAS(ON) inhibitor that could reshape treatment for a disease long dominated by chemotherapy.
Could RAS-targeted therapy be the breakthrough researchers have been waiting for?
Read the full article in CancerWorld by Mariam Khachatryan.”
More posts about CancerWorld.